21.16
Uniqure Nv Borsa (QURE) Ultime notizie
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - Moomoo
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
Transcript: uniQure Q1 2026 Earnings Conference Call - Benzinga
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - Yahoo Finance
MSN Money - MSN
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy - BioPharma Dive
uniQure (NASDAQ:QURE) Shares Gap UpHere's Why - MarketBeat
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure advances AMT-130 toward UK marketing approval - TipRanks
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
uniQure NV | 8-K: Current report - Moomoo
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - Yahoo Finance
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
UniQure to Announce First Quarter 2026 Financial Results - marketscreener.com
uniQure to Announce First Quarter 2026 Financial Results - GlobeNewswire
uniQure NV (MEX:QUREN) Stock Earnings Transcripts - GuruFocus
uniQure NV | DEF 14A: Definitive information statements - Moomoo
uniQure NV | ARS: Annual Report to Security Holders - Moomoo
uniQure (NASDAQ: QURE) outlines 2026 proxy agenda, equity and charter changes - Stock Titan
[ARS] uniQure N.V. SEC Filing - Stock Titan
(QURE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
uniQure announces $200 million proposed public offering - MSN
QURE Forecast, Price Target & Analyst Ratings | UNIQURE NV (NASDAQ:QURE) - ChartMill
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire) - Aktiellt
uniQure N.V. (QURE) Stock Outlook | Q4 2025: Profit Exceeds ViewsROCE - Xã Châu Thành
uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year - Insider Monkey
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):